ALLMedicine™ Hypereosinophilic Syndrome Center
Research & Reviews 297 results
https://doi.org/10.1148/rg.220004
Radiographics : a Review Publication of the Radiological ... Yalon M, Tahboub Amawi AD et. al.
Jun 25th, 2022 - Eosinophilic gastrointestinal disorders (EGIDs) are inflammatory conditions of the gastrointestinal tract that are characterized by tissue eosinophilia and end-organ dysfunction or damage. Primary EGIDs are associated with atopy and other allergic...
https://clinicaltrials.gov/ct2/show/NCT04128371
Jun 24th, 2022 - Episodic angioedema with eosinophilia (EAE), also known as Gleich s Syndrome,is a rare disorder characterized by recurrent episodes of urticaria, fever, angioedema, weight gain and dramatic eosinophilia that occur at 3- to 6-week intervals and res...
https://clinicaltrials.gov/ct2/show/NCT00044304
Jun 24th, 2022 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...
https://clinicaltrials.gov/ct2/show/NCT04191304
Jun 7th, 2022 - This is a multicentre, randomised, double-blind (DB), parallel-group, placebo-controlled, 24-week Phase 3 study to compare the efficacy and safety of benralizumab versus placebo administered by SC injection Q4W in patients with hypereosinophilic s...
https://clinicaltrials.gov/ct2/show/NCT04965636
Jun 3rd, 2022 - The purpose of this study is to investigate the efficacy and safety of mepolizumab in children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard of care (SoC) therapy.
Drugs 9 results see all →
Clinicaltrials.gov 27 results
https://clinicaltrials.gov/ct2/show/NCT04128371
Jun 24th, 2022 - Episodic angioedema with eosinophilia (EAE), also known as Gleich s Syndrome,is a rare disorder characterized by recurrent episodes of urticaria, fever, angioedema, weight gain and dramatic eosinophilia that occur at 3- to 6-week intervals and res...
https://clinicaltrials.gov/ct2/show/NCT00044304
Jun 24th, 2022 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...
https://clinicaltrials.gov/ct2/show/NCT04191304
Jun 7th, 2022 - This is a multicentre, randomised, double-blind (DB), parallel-group, placebo-controlled, 24-week Phase 3 study to compare the efficacy and safety of benralizumab versus placebo administered by SC injection Q4W in patients with hypereosinophilic s...
https://clinicaltrials.gov/ct2/show/NCT04965636
Jun 3rd, 2022 - The purpose of this study is to investigate the efficacy and safety of mepolizumab in children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard of care (SoC) therapy.
https://clinicaltrials.gov/ct2/show/NCT05334368
Apr 19th, 2022 - This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy. The study will recruit patients with a confirmed diagnosis ...
News 9 results
https://www.onclive.com/view/next-generation-of-pdgfr-inhibitors-makes-headway-in-gist
May 25th, 2021 - Dysregulated platelet-derived growth factor receptor (PDGFR) signaling is implicated in a number of cancer types and is among the targets of many FDA-approved multikinase inhibitors.1,2 Despite the success of these drugs in a range of malignancies...
https://www.onclive.com/view/dr-mesa-on-upcoming-updates-to-nccn-guideline-for-mpns
Dec 20th, 2020 - Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses updates that are expected in 2017 to the NCCN Guideline for Myeloproliferative Neoplasms (MPNs). The NCCN Guidelines for Myeloproliferative Neoplasms (version 1.2017), which include t...
https://www.medscape.com/viewarticle/938221
Sep 28th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older wit...
https://www.staging.medscape.com/viewarticle/938221
Sep 28th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older wit...
https://www.mdedge.com/hematology-oncology/article/185423/cythemias/chmp-recommends-approval-generic-imatinib
HT Staff
Sep 18th, 2017 - Photo by Patrick Pelletier Imatinib tablet cut with a pill splitter The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Imatinib Teva B. V.